Celiac Disease Genetic Testing: What HLA-DQ2 and DQ8 Mean for You

Could your DNA explain why bread makes you sick - or prove that it shouldn't? Celiac disease affects roughly 1% of the global population, but up to 83% of people with the condition remain undiagnosed (Singh et al., 2018). A simple genetic test can't tell you whether you have celiac disease, but it can tell you something almost as valuable: whether you're genetically capable of developing it.

The answer comes down to two genes: HLA-DQ2 and HLA-DQ8. If you don't carry either one, you can essentially rule out celiac disease with over 99% confidence (Wolters & Wijmenga, 2008). Here's what that means and why it matters.

What Is Celiac Disease?

Celiac disease is an autoimmune disorder triggered by gluten, a protein found in wheat, barley, and rye. When someone with celiac disease eats gluten, their immune system attacks the lining of the small intestine, destroying the finger-like projections called villi that absorb nutrients (Green & Cellier, 2007).

This isn't a food sensitivity or intolerance - it's a full-blown autoimmune response. Left untreated, celiac disease can cause:

• Iron-deficiency anemia from malabsorption
• Osteoporosis due to poor calcium uptake
• Infertility and miscarriage
• Neurological problems including peripheral neuropathy
• Increased risk of intestinal lymphoma (Lebwohl et al., 2018)

The global prevalence is estimated at 1.4% based on serological testing and 0.7% by biopsy confirmation, with rates ranging from 0.7% to 2.9% depending on the population studied (Singh et al., 2018). Women are affected roughly 1.5 to 2 times more often than men.

The Genetics: Why HLA-DQ2 and HLA-DQ8 Matter

Celiac disease requires a specific genetic setup. The HLA (Human Leukocyte Antigen) system is your immune system's identification toolkit - it helps your body distinguish between your own cells and foreign invaders. Two particular HLA variants play a starring role in celiac disease:

• HLA-DQ2.5 - found in approximately 90–95% of celiac patients. Encoded by the HLA-DQA1*05 and HLA-DQB1*02 alleles (Sollid et al., 1989).
• HLA-DQ8 - found in the remaining 5–10% of patients. Encoded by HLA-DQA1*03 and HLA-DQB1*03:02 (Karell et al., 2003).

Here's the critical concept: these HLA molecules sit on the surface of immune cells and present fragments of gluten (specifically gliadin peptides) to T cells. In people with DQ2 or DQ8, the shape of these molecules is particularly effective at binding and displaying gluten fragments, triggering the destructive immune response (Lundin et al., 1993).

Think of it like a lock and key. The DQ2/DQ8 molecules are locks that happen to fit gluten-derived keys perfectly. Without these locks, the immune cascade that causes celiac disease simply cannot begin.

Necessary But Not Sufficient: The 3% Rule

Here's where it gets interesting - and where many people misunderstand their results. Carrying HLA-DQ2 or DQ8 does not mean you will develop celiac disease.

Approximately 30–40% of the general population carries HLA-DQ2 or DQ8, but only about 3% of carriers actually develop celiac disease (Lionetti et al., 2020). The genes are necessary but not sufficient. You need the genetic susceptibility plus additional factors:

• Environmental triggers - gluten exposure is required, but the timing and amount may matter. Infections, particularly gastrointestinal ones, have been implicated as triggers (Stene et al., 2006).
• Gut microbiome changes - alterations in intestinal bacteria may increase permeability and immune activation (Cenit et al., 2015).
• Other genetic factors - genome-wide association studies have identified over 40 non-HLA loci contributing small amounts of additional risk, including genes involved in immune regulation like IL2, IL21, and CTLA4 (Trynka et al., 2011).
• Life events - pregnancy, surgery, severe stress, and viral infections have all been reported as celiac disease triggers in genetically susceptible individuals (Lebwohl et al., 2018).

The gene dosage also matters. People with two copies of DQ2 (homozygous) have roughly a 10% risk of developing celiac disease, compared to about 3% for single-copy carriers (National Celiac Association, 2025).

What Genetic Testing Can - and Can't - Tell You

HLA-DQ testing is unique among genetic tests because its greatest power is exclusionary. The negative predictive value is extraordinary: if you test negative for both HLA-DQ2 and HLA-DQ8, the probability of developing celiac disease is less than 1% (Wolters & Wijmenga, 2008).

What genetic testing CAN do:

• Virtually rule out celiac disease if DQ2 and DQ8 are both absent
• Identify family members who need monitoring
• Clarify ambiguous antibody test results
• Help evaluate patients already on a gluten-free diet (where antibody tests may be falsely negative)

What genetic testing CANNOT do:

• Diagnose celiac disease (a positive gene test only shows susceptibility)
• Tell you whether you'll ever develop the condition
• Replace antibody testing (tTG-IgA) or intestinal biopsy for diagnosis

This makes HLA testing particularly valuable for family screening. If a first-degree relative has celiac disease, your risk jumps to 5–20% (USPSTF, 2017). Testing family members for HLA-DQ2/DQ8 can immediately remove 60–70% of relatives from the "need to monitor" category - those who don't carry either gene can be reassured.

Understanding Your Raw DNA Data

If you've done consumer genetic testing through 23andMe or AncestryDNA, your raw data file may contain the SNPs used to infer HLA-DQ2 and HLA-DQ8 status. Key markers include:

• rs2187668 - tags HLA-DQ2.5 (the highest-risk variant)
• rs7454108 - tags HLA-DQ8

A GG genotype at rs2187668 indicates two copies of the DQ2.5 tag SNP (highest risk). AG indicates one copy. AA indicates absence of DQ2.5.

However, HLA typing from consumer SNP arrays is imperfect - the HLA region is one of the most complex and variable parts of the human genome. Clinical-grade HLA typing through a certified lab provides more definitive results. Services like GenomeInsight can help you interpret these markers from your raw data as a starting point.

Who Should Get Tested?

Current guidelines recommend considering HLA-DQ testing for:

• First-degree relatives of someone with confirmed celiac disease (Husby et al., 2012)
• People with type 1 diabetes - celiac disease co-occurs in 3–16% of type 1 diabetics (Camarca et al., 2012)
• Individuals with Down syndrome, Turner syndrome, or Williams syndrome - all carry elevated celiac risk
• People with other autoimmune conditions - autoimmune thyroiditis, autoimmune liver disease, IgA deficiency
• Patients already on a gluten-free diet without prior diagnosis - antibody tests require active gluten consumption, but HLA testing works regardless of diet

If you've already uploaded your raw DNA data, check your genetic health report to see whether your data includes markers related to celiac susceptibility. For a deeper understanding of how your genes influence your response to medications and conditions, explore our pharmacogenomics guide.

What to Do If You Carry DQ2 or DQ8

Carrying the gene doesn't mean going gluten-free preemptively. Here's a practical approach:

• Get baseline antibody testing - ask your doctor for a tissue transglutaminase IgA (tTG-IgA) test. This is the first-line screening test for active celiac disease (Rubio-Tapia et al., 2013).
• Stay on a gluten-containing diet until testing is complete - removing gluten before testing can cause false negatives.
• Know the symptoms - celiac disease can present as digestive problems (diarrhea, bloating, weight loss) or with non-GI symptoms like fatigue, joint pain, skin rash (dermatitis herpetiformis), or unexplained anemia.
• Retest periodically - celiac disease can develop at any age. If you carry the genes and have a family history, periodic antibody screening (every 2–3 years) is reasonable.
• Monitor children - if you have celiac disease, your children have a 5–20% chance of developing it. HLA testing can guide whether they need ongoing surveillance.

Key Takeaways

• HLA-DQ2 and HLA-DQ8 are required for celiac disease - without them, the condition is virtually excluded (>99% negative predictive value).
• 30–40% of people carry these genes, but only ~3% of carriers develop celiac disease. Genes are necessary but not sufficient.
• Homozygous DQ2 carriers have roughly a 10% lifetime risk - three times higher than single-copy carriers.
• Family members of celiac patients have a 5–20% risk and should consider HLA screening to determine who needs ongoing monitoring.
• Genetic testing cannot diagnose celiac disease - it identifies susceptibility. Diagnosis requires antibody testing and/or biopsy.
• Your raw DNA data from consumer tests may contain relevant markers. Upload your data to GenomeInsight to explore your genetic predispositions, including celiac-related HLA markers.

Stay informed about the latest in genetic health - subscribe to our newsletter for evidence-based insights delivered to your inbox.

References

Camarca, M. E., Mozzillo, E., Nugnes, R., Zito, E., Falco, M., Fattorusso, V., Lombardi, F., Franzese, A., & Troncone, R. (2012). Celiac disease in type 1 diabetes mellitus. Italian Journal of Pediatrics, 38, 10. https://doi.org/10.1186/1824-7288-38-10

Cenit, M. C., Olivares, M., Codoñer-Franch, P., & Sanz, Y. (2015). Intestinal microbiota and celiac disease: Cause, consequence or co-evolution? Nutrients, 7(8), 6900–6923. https://doi.org/10.3390/nu7085314

Green, P. H. R., & Cellier, C. (2007). Celiac disease. New England Journal of Medicine, 357(17), 1731–1743. https://doi.org/10.1056/NEJMra071600

Husby, S., Koletzko, S., Korponay-Szabó, I. R., Mearin, M. L., Phillips, A., Shamir, R., Troncone, R., Giersiepen, K., Branski, D., Catassi, C., Lelgeman, M., Mäki, M., Ribes-Koninckx, C., Ventura, A., & Zimmer, K. P. (2012). European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. Journal of Pediatric Gastroenterology and Nutrition, 54(1), 136–160. https://doi.org/10.1097/MPG.0b013e31821a23d0

Karell, K., Louka, A. S., Moodie, S. J., Ascher, H., Clot, F., Greco, L., Ciclitira, P. J., Sollid, L. M., & Partanen, J. (2003). HLA types in celiac disease patients not carrying the DQA105-DQB102 (DQ2) heterodimer. Human Immunology, 64(4), 469–477. https://doi.org/10.1016/S0198-8859(03)00027-2

Lebwohl, B., Sanders, D. S., & Green, P. H. R. (2018). Coeliac disease. The Lancet, 391(10115), 70–81. https://doi.org/10.1016/S0140-6736(17)31796-8

Lionetti, E., Castellaneta, S., Francavilla, R., Pulvirenti, A., Tonutti, E., Amarri, S., Barbato, M., Barbera, C., Barera, G., Bellantoni, A., Castellano, E., Guariso, G., Limongelli, M. G., Pellegrino, S., Polloni, C., Ughi, C., Zuin, G., Fasano, A., & Catassi, C. (2020). Introduction of gluten, HLA status, and the risk of celiac disease in children. New England Journal of Medicine, 371(14), 1295–1303. https://doi.org/10.1056/NEJMoa1400697

Lundin, K. E., Scott, H., Hansen, T., Paulsen, G., Halstensen, T. S., Fausa, O., Thorsby, E., & Sollid, L. M. (1993). Gliadin-specific, HLA-DQ(alpha 10501, beta 10201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. Journal of Experimental Medicine, 178(1), 187–196. https://doi.org/10.1084/jem.178.1.187

Rubio-Tapia, A., Hill, I. D., Kelly, C. P., Calderwood, A. H., & Murray, J. A. (2013). ACG clinical guidelines: Diagnosis and management of celiac disease. American Journal of Gastroenterology, 108(5), 656–676. https://doi.org/10.1038/ajg.2013.79

Singh, P., Arora, A., Strand, T. A., Leffler, D. A., Catassi, C., Green, P. H., Kelly, C. P., Ahuja, V., & Makharia, G. K. (2018). Global prevalence of celiac disease: Systematic review and meta-analysis. Clinical Gastroenterology and Hepatology, 16(6), 823–836. https://doi.org/10.1016/j.cgh.2017.06.037

Sollid, L. M., Markussen, G., Ek, J., Gjerde, H., Vartdal, F., & Thorsby, E. (1989). Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. Journal of Experimental Medicine, 169(1), 345–350. https://doi.org/10.1084/jem.169.1.345

Stene, L. C., Honeyman, M. C., Hoffenberg, E. J., Haas, J. E., Sokol, R. J., Emery, L., Taki, I., Norris, J. M., Erlich, H. A., Eisenbarth, G. S., & Rewers, M. (2006). Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood. American Journal of Gastroenterology, 101(10), 2333–2340. https://doi.org/10.1111/j.1572-0241.2006.00741.x

Trynka, G., Hunt, K. A., Bockett, N. A., Romanos, J., Mistry, V., Szperl, A., Bakker, S. F., Bardella, M. T., Bhaw-Rosun, L., Castillejo, G., de la Concha, E. G., de Almeida, R. C.,"; Dias, K. R., van Diemen, C. C.,"; Dubois, P. C.,"; Duerr, R. H., Edkins, S., Franke, L., Fransen, K., ... van Heel, D. A. (2011). Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nature Genetics, 43(12), 1193–1201. https://doi.org/10.1038/ng.998

Wolters, V. M., & Wijmenga, C. (2008). Genetic background of celiac disease and its clinical implications. American Journal of Gastroenterology, 103(1), 190–195. https://doi.org/10.1111/j.1572-0241.2007.01471.x

---

Related Reading

• HLA-DQ2 molecular genetics
• rheumatoid arthritis genetics
• lactose intolerance genetics